NYSE: $MRK A New Frontier in Autoimmune Research Merck has officially shared positive one-year results from its pivotal Phase 2b/3 Brunello clinical trial. The study is evaluating the safety and efficacy of remigromig, an investigational anti-PD-1 therapy, specifically targeting patients living with moderate-to-severe systemic lupus erythematosus (SLE). Understanding the Brunello Study The Brunello trial is…